scholarly journals Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study

2019 ◽  
Vol 10 (17) ◽  
pp. 4151-4158
Author(s):  
Yu-Feng Wei ◽  
Wen-Tsung Huang ◽  
Tu-Chen Liu ◽  
Jiunn-Min Shieh ◽  
Chih-Feng Chian ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Factors Associated ◽  
Egfr Mutated ◽  
Inhibitor Treatment

Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice

2015 ◽  
Vol 25 (6) ◽  
pp. 1441-1449 ◽  
Author(s):  
Szu-Chun Yang ◽  
Wu-Wei Lai ◽  
Tzuen-Ren Hsiue ◽  
Wu-Chou Su ◽  
Cheng-Kuan Lin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Small Cell ◽  
Health Related Quality ◽  
Small Cell Lung ◽  
First Line ◽  
Cancer Treatments ◽  
Anti Cancer ◽  
Related Quality ◽  
Health Related

scholarly journals Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer

2018 ◽  
Vol 10 ◽  
pp. 175883401875507 ◽  
Author(s):  
Szu-Chun Yang ◽  
Chien-Chung Lin ◽  
Wu-Wei Lai ◽  
Sheng-Mao Chang ◽  
Jing-Shiang Hwang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mixed Models ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Dynamic Changes

Background: Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) for patients using these therapies after controlling for potential confounders. Methods: From 2011 to 2016, we prospectively assessed the utility values and QoL scores of patients using the EuroQol five-dimension and World Health Organization Quality-of-Life – Brief questionnaires. QoL functions after initiation of treatment were estimated using a kernel-smoothing method. Dynamic changes in major determinants were repeatedly assessed for constructing mixed models. Results: A total of 344 patients were enrolled, with 934 repeated assessments. After controlling for performance status, disease progression, EGFR mutation subtype and other confounders, the mixed models showed significantly lower QoL scores for afatinib versus gefitinib in the physical, psychological and social domains, and 10 facets. The differences seemed to appear 10 months after initiation of treatment. In contrast, there was no significant difference between erlotinib and gefitinib in the scores of all domains and facets. Conclusion: QoL in patients receiving afatinib seemed to be lower than in those receiving gefitinib. Since the sample sizes in this study were relatively small, more studies are warranted to corroborate these results.

Sign in / Sign up

Export Citation Format

Share Document